In order to verify whether the new combi-molecule could target BRCA1/2 mutants, we analyzed the potency of EG22 against the pair of Chinese Hamster lung cancer cell line: with V79, a BRCA1/2-proficient and the other VC8 BRCA1/2-mutant. This evidence concerns the gene BRCA1 and lung cancer.